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Human fibroblast activation protein (FAP) is a 97-kDa surface glycoprotein expressed in 
tumor-associated fibroblasts.  In this study, we immunohistochemically examined FAP 
levels in surgically resected gastric carcinomas and explored their association with clini-
copathological findings and prognosis.  Sections of paraffin-embedded specimens were 
obtained from 100 patients with advanced gastric cancer between 1989 and 2001 at our 
institution, and they were stained with an anti-FAP antibody.  Expression of FAP was 
detected in 64 patients (64%).  Lymphatic vessel invasion was observed in 90% of FAP-
positive patients (P = 0.015).  Blood vessel invasion was observed in 98% of FAP-positive 
patients (P < 0.001).  The disease-specific 5-year survival rate of in the 64 patients with 
FAP-positive tumors (22%) was significantly lower than in the 36 patients with FAP-
negative tumors (34%, P = 0.036).  This indicates that vessel invasion is connected with 
the expression of FAP and that a positive finding of FAP confer a worse prognosis in the 
patients with gastric cancer.
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Gastric cancer is one of the most malignant tumor 
types having a dismal prognosis.  Lymph node 
metastasis, hematogenic metastasis, and perito-
neal metastasis have all been reported to have a 
strong impact on prognosis for gastric cancer pa-
tients.  Tumor cell invasion and subsequent distant 
spread via blood and lymph vessels are critical 
steps in tumor progression.  In the process of tis-
sue invasion and metastasis, cancer cells produce 
enzymes that degrade basement membranes and 
extracellular matrix (Liotta et al., 1991).  During 
disease progression, interactions between cancer 
cells and mesenchyme-derived stromal cells, such 
as fibroblasts, myofibroblasts, endothelial cells, 
smooth muscle and hematopoietic cells occur. 
However, the relationship between cancer cells 
and mesenchyme-derived stromal cells has not 
been well described (Mueller and Fusenig, 2004; 
Huber et al., 2005; Joyce, 2005; Orimo et al., 2005; 
Kalluri and Zeisberg, 2006; Elinborg et al., 2008).  
 Human fibroblast activation protein (FAP) 
is a 97-kDa cell surface glycoprotein with gelati-
nase and depeptidyl peptidase activity (Pineiro-
Sanchez et al., 1997; Park et al., 1999).  This 
protein is expressed in stromal fibroblasts located 
in and around the tumor.  The distribution of 
FAP is unique.  FAP is not expressed by normal 
fibroblasts, but is expressed transiently in heal-
ing wound tissues (Ghersi et al., 2002), chronic 
inflammatory conditions such as cirrhosis (Levy 
et al., 2002) and some fetal mesenchymal tissues. 
Recently, FAP produced by stromal fibroblasts 
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was reported to play an important role in tumor 
cell progression (Allinen et al., 2004; Narra et al., 
2007).  Cheng et al. (2002) reported that forced 
FAP overexpression by tumor cells in an animal 
model results in a significant enhancement of tu-
mor growth.
 In the present study, we investigated the clin-
ical significance of stromal fibroblast FAP expres-
sion in gastric cancer by the immunohistochemi-
cal examination.  We examined the relationship 
between FAP expression and clinicopathological 
findings in patients with gastric cancer.  We also 
comment on the clinical importance of FAP ex-
pression in stromal fibroblasts. 
 
 
Materials and Methods
 
Patients
 
The medical records of corresponding patients 
were retrospectively reviewed.  The 100 primary 
gastric cancer patients were enrolled in this study. 
The stages of their tumors were III and IV.  They 
underwent gastrectomy at our institution between 
1989 and 2001.  The age of patients ranged from 
33 to 93 years (average 66.3 years); 72 were male 
and 28 were female.  The clinicopathological 
findings were described according to the Japanese 
Classification of Gastric Cancer by our hospital 
pathologists (Japan Research Society for Gastric 
Cancer, 1995).  All patients had undergone distal, 
proximal or total gastrectomy with dissection of 
level 1 and 2 regional lymph nodes (D2).  Cura-
tive operations were performed in all patients. 
The follow-up periods for survivors ranged from 1 
to 180 months (median, 39 months) after surgery. 
Informed consent was obtained from all subjects 
and/or their guardians.
 
Immunohistochemistry
 
A streptavidin-biotin kit (Histofine SAB-PO kit; 
Nichirei, Tokyo, Japan) was used for staining of 
formalin-fixed and paraffin-embedded specimens. 
Specimens were dewaxed in xylene, rehydrated 
in ethanol, treated with 0.3% hydrogen peroxide 
in methanol for 15 min, and then heated in an 
autoclave oven (120˚C) for 20 min.  They were 
then washed with phosphate-buffered saline 
(PBS) and preblocked with 10% gout saline for 10 
min.  After washing with PBS, the samples were 
incubated overnight at 4˚C with an anti-FAP poly-
clonal anitibody (ab53066; Abcam, Tokyo) diluted 
at 1:50.  Specimens were then washed in PBS and 
incubated with anti-rabbit immunoglobulin con-
jugated to biotin for 10 min, followed by incuba-
tion with a streptavidin peroxidase complex for a 
further 5 min.  Following another wash with PBS, 
immunohistochemical labeling was visualized 
using freshly prepared diaminobenzidine tetra-
hydrochloride. Sections were counterstained with 
hematoxylin.
 
Scoring system
 
Stromal fibroblasts with FAP immunoreactivity 
were quantified by 2 independent observers who 
evaluated at least 1,000 fibroblasts in consecu-
tive sections of neoplastic tissues.  Stromal fibro-
blasts were classified into two categories based 
on FAP expression:  i) negative staining (negative 
or equivocal staining or when less than 10% cells 
were detected) and ii) positive staining (when 10% 
or more cells were detected). 
 
 
Statistical analysis 
 
The chi-square test was used to compare the 
differences between the two groups.  The sig-
nificance of differences among means was deter-
mined by the Mann-Whitney U test.  The overall 
and disease-free survival periods were estimated 
using the Kaplan-Meier method and compared us-
ing a two-sided log rank test.  Cox’s proportional 
hazards regression model was used to estimate the 
predictive power of FAP expression on clinical 
outcome.  Two-sided tests were computed, and P 
< 0.05 was considered statistically significant. 
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Results
 
FAP expression and clinicopathological 
findings
 
FAP expression was detected in stromal fibro-
blasts around or within cancer tissue (Fig. 1).  It 
was not detected in cancer cells or stromal cells 
located in normal gastric tissues in the resected 
specimens. FAP-positive stromal fibroblasts were 
detected in 64 patients (64%).  The clinicopatho-
logical characteristics of the 64 patients with 
FAP-positive stromal fibroblasts were compared 
with those of the 36 patients who were FAP nega-
tive (Table 1).  Lymphatic vessel invasion was ob-
served in 90% of FAP-positive patients compared 
with 70% of FAP-negative patients (P = 0.015). 
Blood vessel invasion was observed in 98% of the 
former group compared with 19% of the latter 
group (P < 0.001).  There was no significant dif-
ference with FAP expression level and histological 
type of gastric cancer.
  
Table 1.  Expression of FAP and clinicopathological parameters
 FAP expression  P value
 Positive Negative
Age (year)  67.2 ± 11.7 64.6 ± 9.8 0.26
Gender Male 47 25 0.8169
 Female 17 11
Tumor size (cm)  8.6 ±  3.7 7.6 ± 3.9 0.23
Cancer stroma relationship Med, Int  31  17 0.0760
 Sci    31  20
Histology* Differentiated 24 12 0.8285
 Undifferentiated 40 24
Lymph node metastasis Absent 3 6 0.3536
 Present 61 30
Lymphatic vessel invasion Absent 6 11 0.0151
 Present 58 25
Blood vessel invasion Absent 1 29 < 0.0001
 Present 63 7
Stage III 43 29 0.172
 IV 21 7
 FAP, fibroblast activation protein; Int, intermediate type; Med, medullary type; Sci, scirrhous type. 
* Differentiated, papillary or tubular adenocarcinoma; undifferenciated, poorly differenciated or undifferenciated ad-
enocarcinoma or signet ring cell carcinoma.
Fig. 1.  Immunohistochemical staining pattern for FAP 
in a gastric carcinoma.  Expression of FAP is detected in 
stromal fibroblasts.  Bar = 50 µm. 
 
Prognosis of patients
 
The overall 5-year survival rate among the 100 
patients with stage III and IV gastric cancer was 
29%.  The disease-specific 5-year survival rate 
among the 64 patients with FAP-positive tumors 
(22%) was significantly lower than that of the 36 
patients with FAP-negative tumors (34%, P = 0.036, 
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Fig. 2).  Multivariate analysis was performed with 
a Cox proportional hazards model using the co-
variates of tumor histology, histological stage and 
expression of FAP (Table 2).  FAP expression was 
not detected as a prognostic factor independent of 
the histological stage (P = 0.072).
 
Discussion
In the present study, we have immunohistochemi-
cally demonstrated the frequent occurrence of 
FAP expression in surgically resected gastric 
Table 2.  Multivariate survival analysis by the 
Cox proportional hazards model
        Variable Hazard 95%  P
 ratio Confidence value
  interval
Tumor histology* 
     Differentiated/
        undifferentiated  0.861 0.542–1.368 0.527
Histological stage 
     Stage III/IV 3.39 2.044–5.622 < 0.001
FAP expression
     Positive/negative 1.557 0.956–2.535 0.072
 FAP, fibroblast activation protein. 
* Differentiated, papillary or tubular adenocarcinoma; 
undifferenciated, poorly differenciated or undifferenci-
ated adenocarcinoma or signet ring cell carcinoma.
Fig. 2.  Survival is estimated using the Kaplan-Meier 
methods, which produce the disease-specific survival 
curves of patients with stage III and IV gastric carci-
noma according to the expression of FAP.  FAP-positive 
cases have lower survival rates.
cancer.  Our data showed that FAP expression is 
correlated with lymphatic and blood vessel inva-
sion and caused a worse prognosis in patients 
with advanced gastric cancer.  FAP expression 
has been described to be present predominantly 
in the tumor stroma of epithelial malignancies 
(Garin-Chese et al., 1990; Ariga et al., 2001), and 
its presence has been associated with increased 
microvessel density (Huang et al., 2004).  FAP 
activity has also been suggested to participate in 
the growth of human colorectal tumor xenografts, 
because inhibition of FAP enzymatic activity in 
these tumors resulted in tumor growth attenuation 
(Cheng et al., 2002; Cheng et al., 2005).  We have 
found strong relationship between FAP expres-
sion in tumor-associated fibroblast and invasion of 
cancer cells into microvessels of the gastric wall. 
These reports suggest that FAP-dependent path-
ways may play an important role in epithelial can-
cer invasion, tumor angiogenesis, and subsequent 
growth and metastasis. 
 We have found a statistically significant as-
sociation between the expression of FAP and 
shortened survival time in patients.  We have also 
found that the expression of FAP is an indepen-
dent prognostic factor as well as the histologi-
cal stage.  It has been proposed that scirrhous 
gastric cancer has a worse prognosis, but in our 
study there was no siginificant difference in FAP 
expression between patients with scirrhous-type 
cancer and other types of cancer (P = 0.076).  FAP 
pathways may predominate early in the course of 
smaller tumors to facilitate tumor invasion and 
tumor motility, which are required for metastases 
to occur, thus leading to the enhanced induction 
of FAP expression in early-stage disease.  In ad-
vanced tumors, a relatively persistent elevation of 
FAP levels may signify a more aggressive tumor 
and a continued additive contribution of FAP-de-
pendent pathways to tumor invasion and growth. 
Thus high FAP levels may confer a worse progno-
sis even in those with advanced disease (Leonard 
et al., 2007).
 In conclusion, we found that stromal FAP 
levels are related to stage III and IV gastric can-
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cer, and that the expression of FAP is associated 
with decreased survival time.  If successful, stro-
ma-directed therapy may provide clinical benefits 
in a broad spectrum of indications, based on the 
consistent presence and remarkable abundance of 
stromal compartments in human carcinomas.
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